March 25, 2015
ViroCyt, LLC, the leader in rapid virus quantification, announced today the introduction of the next generation Virus Counter at the World Vaccine Congress being held in Washington, DC. The Virus Counter technology has already been adopted by the leading companies in the fields of viral vaccine development and therapeutic protein expression. The new system known as the Virus Counter 3100 was developed specifically for manufacturing environments and includes 21 CFR part 11-capable software, a 96-well compatible autosampler, and a new rugged design for use in industrial settings.
“The Virus Counter 3100 will allow our customers to extend the benefits of rapid virus quantification into their high volume process development and manufacturing operations. Our customers have clearly communicated their desire to move the Virus Counter technology beyond their research labs and ViroCyt has responded with new and enhanced capabilities which have been incorporated into the Virus Counter 3100,” stated Robert Kline, President and CEO of ViroCyt, LLC. “The 3100 launch coincides with the World Vaccine Congress at which several Virus Counter users – Sanofi Pasteur and the FDA – are speaking about the value of rapid virus quantification at their organizations.”
First introduced in 2011, the Virus Counter has proven to be faster, more accurate and cost effective than traditional viral quantification methods such as plaque titer, tissue culture infective dose, electron microscopy and quantitative PCR. The Virus Counter provides results in minutes instead of days or weeks which is vital when monitoring complex and expensive viral production processes.
ViroCyt, LLC was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. Additional information can be found at www.virocyt.com.